Cranbury Pharmaceuticals has begun shipping the first US generic version of PTC Therapeutics’ Emflaza (deflazacort) oral suspension for the treatment of Duchenne muscular dystrophy, after the brand’s seven-year period of orphan drug exclusivity for treatment of DMD in patients five years and older expired in February this year.
The New Jersey-based company is a new subsidiary of Tris Pharma, which has handed over its generics portfolio and pipeline...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?